Press Release Archive
-
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter ResultsJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
-
DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple MyelomaDARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma· First Phase 3 study showing addition of the CD38-directed antibody DARZALEX® to carfilzomib in combination with dexamethasone
· Data selected as a Late-Breaking Abstract at ASH 2019 -
DARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for TransplantDARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant· Updated data from the Phase 3 ALCYONE study showed an overall survival benefit and continued improvement in progression-free survival after a median duration of follow-up of more than three years with DARZALEX®; results simultaneously published in The Lancet
· DARZALEX® is the only CD38-directed antibody to show an overall survival benefit in multiple myeloma
· Additionally, follow-up data from the Phase 3 MAIA study showed significant progression-free survival benefit continuing for three years following DARZALEX® treatment -
IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic LeukemiaIMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia· Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of IMBRUVICA® in combination with rituximab versus fludarabine, cyclophosphamide and rituximab showed statistically significant difference in progression-free survival (PFS) and overall survival (OS) were maintained in previously untreated patients (ages 70 or younger) with chronic lymphocytic leukemia (CLL)
· Integrated analysis from RESONATETM and RESONATETM-2 studies in CLL (Abstract #3054) reported long-term PFS, OS and response rates with earlier treatment with IMBRUVICA®
· IMBRUVICA® plus venetoclax data from Phase 2 CAPTIVATE study (Abstract #35) showed high rates of undetectable minimal residual disease (uMRD) in peripheral blood (75 percent of patients) and in bone marrow (72 percent of patients) in previously untreated patients with CLL for time-limited, MRD-guided combination regimen -
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple MyelomaJanssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple MyelomaResults from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at ASH 2019 (Abstract #577)
-
Janssen to Acquire Investigational Bermekimab from XBiotechJanssen to Acquire Investigational Bermekimab from XBiotechClinical Stage, First-in-Class Anti-IL-1a Antibody for Atopic Dermatitis and Hidradenitis Suppurativa
-
Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple MyelomaJanssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple MyelomaNewest designation for JNJ-4528 is supported by Phase 1b/2 CARTITUDE-1 study in adults with relapsed or refractory multiple myeloma
Initial results from CARTITUDE-1 study to premiere at the American Society of Hematology Annual Meeting -
Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola OutbreakJohnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola OutbreakUp to 200,000 Regimens of Janssen’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC)
-
Johnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of DirectorsJohnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of Directors
-
Company Investigation Confirms No Asbestos in Johnson’s Baby PowderCompany Investigation Confirms No Asbestos in Johnson’s Baby PowderMore Than 150 Tests Show No Asbestos